Kangyuan Pharmaceuticals WXSH0493 tablets were approved clinically.

Guide: WXSH0493 is a highly active and safe URAT1 inhibitor.
recently, Jiangsu Kangyuan Pharmaceutical Co., Ltd. declared WXSH0493 tablets received the State Drug Administration issued the "Drug Clinical Trial Approval Notice" (No. 2020LP00161 / 2020LP00162), agreed to the drug for clinical trials.
Gout and high uric acidemia have gradually become a class of serious metabolic diseases, the incidence rate is increasing year by year, and closely related to a series of complications, the current first-line drug has poor efficacy, side effects and other defects, at the same time in patients have certain restrictions on use.
lesinurad, the first URAT1 inhibitor drug to be marketed, showed only moderate ller effects and more clinical toxic side effects in multiple Phase III clinical trials.
WXSH0493 is specifically designed based on the problems exposed by lesinurad in clinical applications, focusing on how to improve drug ability, how to reduce OAT4 inhibition, how to avoid highly active metabolic intermediates and other key issues, and achieved positive results.
WXSH0493 will provide a new drug option in the clinical treatment of patients with geryro and hypoureticemia, which is expected to address the unsolved clinical needs of these patients and has significant clinical value.
of this announcement, the Company has invested 22.5858 million yuan in research and development of WXSH0493 tablets.
WXSH0493 is a highly active, high-safety URAT1 inhibitor that is clinically positioned to improve the effectiveness and safety of lesinurad in clinical use, so its market positioning is a first-line drug for glycourine and high uric acidemia.
currently, clinical first-line medications for high uric acidemia and gout mainly include paracetamol, non-clothing, propylene sulfonshu, benzo bromine malone, akidolic and lesinurad.
.